The global multiple sclerosis therapeutic market size was valued at USD 26.18 billion in 2023 and is anticipated to reach around USD 46.44 billion by 2033, growing at a CAGR of 5.9% from 2024 to 2033.
The market growth is due to the rise in the global prevalence of the disease, and the advancements in the treatment which have led to the development of disease-modifying therapies (DMTs) that slow the progression and manage the symptoms more effectively.
The latest technological developments and advancements in multiple sclerosis therapeutics are poised to increase growth opportunities in the forecast period as advancements have significantly improved the quality of life for patients. Some examples of these technologies are assistive robotic arms, smartphone apps, voice commands, and neurotherapy treatments such as transcranial direct current stimulation (tDCS). In addition, the rise in the population suffering from multiple sclerosis coupled with an increasing demand for novel potent drugs is a key factor driving market growth.
The growth is attributed to the increasing focus on research and development to develop innovative drugs by major market players. New product launches and increasing government initiatives to improve the accessibility of treatment and care are expected to result in global market expansion in the forecast period. According to the MS International Federation, the number of people suffering from MS across the globe has increased from 2.3 million in 2013 to 2.8 million in 2020 and 2.9 in 2023. These statistics show the rising prevalence of MS globally which is a key growth driver for the multiple sclerosis therapeutic market in the forecast period.
The healthcare spending and clinical diagnostics & technological advancements have propelled the market growth. Patients suffering from multiple sclerosis can effectively manage their symptoms and enhance their quality of life with the easy availability of oral medications and injections resulting in minimal side effects. There has been a huge demand for oral medications in the past few years. This has led to the entry of new market players with an introduction to generics and biosimilars.
The U.S. multiple sclerosis therapeutic Market size is expected to be worth around USD 12.77 Billion by 2033 from USD 6.99 Billion in 2023, growing at a Compound Annual Growth Rate (CAGR) of 6.2% during the forecast period from 2024 to 2033.
North America dominated the global multiple sclerosis therapeutic market with a share of 38.13% in 2023. The growth is due to increasing cases of multiple sclerosis in the region. Another significant factor contributing to this growth is the presence of advanced healthcare infrastructure in the region.
U.S. Multiple Sclerosis Therapeutic Market Trends
The multiple sclerosis therapeutic market in the U.S. dominated the North America market with a share of 80.8% in 2023 due to the increased awareness leading to early detection of disease. In the U.S., March is celebrated as the Multiple Sclerosis Awareness Month with the support of the Multiple Sclerosis Association of America. According to the National Multiple Sclerosis Society, almost one million people in the U.S. were diagnosed with this condition in 2019. This underscores the rising prevalence of the disorder in the U.S.
Europe Multiple Sclerosis Therapeutic Market Trends
Europe multiple sclerosis therapeutic market emerged as a lucrative region in 2023. This is due to the presence of well-established healthcare infrastructure in the region.
The multiple sclerosis therapeutic market in the UK is expected to grow rapidly in the coming years due to the advanced healthcare infrastructure in the country allowing more precise diagnosis of MS and customized treatment options.
Germany multiple sclerosis therapeutic market held a substantial market share in 2023. This is due to the active government recommendations and favorable healthcare policies in the country.
Asia Pacific Multiple Sclerosis Therapeutic Market Trends
Asia Pacific multiple sclerosis therapeutics market is expected to grow rapidly in the coming years. The area is witnessing a boost due to increased government initiatives, an increase in available treatment options, and lower treatment costs in the region.
The significant market share of multiple sclerosis therapeutic in China in 2023. The growth of the pharmaceutical industry in China is driving the growth of the multiple sclerosis therapeutic market. For instance, the establishment of the China National Registry of Central Nervous System Inflammatory Demyelinating Illnesses in 2021 aimed to provide a comprehensive overview of MS and related diseases and provide disease management for these diseases.
The multiple sclerosis therapeutic market in India held a substantial market share due to several factors such as India’s expanding healthcare infrastructure and initiatives undertaken by the government for the adoption of advanced technologies.
| Report Attribute | Details |
| Market Size in 2024 | USD 27.72 Billion |
| Market Size by 2033 | USD 46.44 Billion |
| Growth Rate From 2024 to 2033 | CAGR of 5.9% |
| Base Year | 2023 |
| Forecast Period | 2024 to 2033 |
| Segments Covered | Drug class, route of administration, distribution channel, region |
| Market Analysis (Terms Used) | Value (US$ Million/Billion) or (Volume/Units) |
| Report Coverage | Revenue forecast, company ranking, competitive landscape, growth factors, and trends |
| Key Companies Profiled | Teva Pharmaceutical Industries Ltd.; Pfizer Inc.; Biogen; Bayer AG; Sanofi; F. Hoffmann-La Roche Ltd; Johnson & Johnson Services, Inc.; Merck & Co., Inc.; Takeda Pharmaceutical Company Limited.; Horizon Therapeutics plc |
The immunosuppressants segment dominated the market with a 60.28% share in 2023.Immunosuppressants play an important role in managing the disease by suppressing this abnormal immune response. Growing new product approvals for multiple sclerosis support the segment's expansion. There are several benefits of these medications such as the need for low dosage for successful administration, fewer adverse effects, and high efficiency are driving the market growth.
The immunostimulants segment is projected to grow at a CAGR of 6.7% over the forecast period. Immunostimulants work by boosting the immune system’s activity which can be beneficial in the cases of multiple sclerosis in which enhancing immune responses helps in fighting the disease progression. With advancements in research and technology, new immunostimulant therapies are being developed that target specific pathways involved in MS pathogenesis, offering promising treatment options for patients.
The injectable segment dominated the market with a share of 52.19% in 2023. The growth of this segment is due to the increasing preference for injectable drugs due to their higher efficacy and convenience. Injectable drugs are also more effective in controlling the disease symptoms than other route of administration.
The oral segment is projected to grow at a CAGR of 7.0% over the forecast period. This growth is due to their convenience and ease of administration. Patients prefer oral medications as they eliminate the need for frequent injections, which can be painful and inconvenient.
The hospital pharmacies segment dominated the market with a share of 46.18% in 2023.This is due to the growing significance of disease and the rise in number of indoor patients. As more individuals are diagnosed with this condition, there is a higher demand for medications to manage the symptoms and progression of the disease and hospitals are well equipped to handle such diseases. Hospitals are becoming key centers for diagnosis and treatment of multiple sclerosis, which is leading to a rise in the distribution of therapeutics through hospital pharmacies.
The retail pharmacies segment is projected to grow at a CAGR of 6.4% over the forecast period. This growth is due to the convenience and accessibility offered by retail pharmacies, which makes them a preferred choice for patients seeking regular refills of their medications.
The following are the leading companies in the multiple sclerosis therapeutic market. These companies collectively hold the largest market share and dictate industry trends.
This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Nova one advisor, Inc. has segmented the Multiple Sclerosis Therapeutic market.
By Drug Class
By Route of Administration
By Distribution Channel
By Region
Chapter 1. Methodology and Scope
1.1. Market Segmentation and Scope
1.2. Market Definitions
1.3. Research Methodology
1.3.1. Information Procurement
1.3.2. Information or Data Analysis
1.3.3. Market Formulation & Data Visualization
1.3.4. Data Validation & Publishing
1.4. Research Scope and Assumptions
1.4.1. List of Data Sources
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.3. Competitive Insights
Chapter 3. Multiple Sclerosis Therapeutic Market Variables, Trends, & Scope
3.1. Market Introduction/Lineage Outlook
3.2. Market Size and Growth Prospects (USD Million)
3.3. Market Dynamics
3.3.1. Market Drivers Analysis
3.3.2. Market Restraints Analysis
3.4. Multiple Sclerosis Therapeutic Market Analysis Tools
3.4.1. Porter’s Analysis
3.4.1.1. Bargaining power of the suppliers
3.4.1.2. Bargaining power of the buyers
3.4.1.3. Threats of substitution
3.4.1.4. Threats from new entrants
3.4.1.5. Competitive rivalry
3.4.2. PESTEL Analysis
3.4.2.1. Political landscape
3.4.2.2. Economic and Social landscape
3.4.2.3. Technological landscape
3.4.2.4. Environmental landscape
3.4.2.5. Legal landscape
Chapter 4. Multiple Sclerosis Therapeutic Market: Drug Class Estimates & Trend Analysis
4.1. Segment Dashboard
4.2. Multiple Sclerosis Therapeutic Market: Drug Class Movement Analysis, 2024 & 2033 (USD Million)
4.3. Immunosuppressants
4.3.1. Immunosuppressants Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
4.4. Immunostimulants
4.4.1. Immunostimulants Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 5. Multiple Sclerosis Therapeutic Market: Route of Administration Estimates & Trend Analysis
5.1. Segment Dashboard
5.2. Multiple Sclerosis Therapeutic Market: Route of Administration Movement Analysis, 2024 & 2033 (USD Million)
5.3. Oral
5.3.1. Oral Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
5.4. Injectable
5.4.1. Injectable Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
5.5. Others
5.5.1. Others Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 6. Multiple Sclerosis Therapeutic Market: Distribution Channel Estimates & Trend Analysis
6.1. Segment Dashboard
6.2. Multiple Sclerosis Therapeutic Market: Distribution Channel Movement Analysis, 2024 & 2033 (USD Million)
6.3. Hospital Pharmacies
6.3.1. Hospital Pharmacies Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
6.4. Retail Pharmacies
6.4.1. Retail Pharmacies Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
6.5. E-Commerce
6.5.1. E-Commerce Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 7. Multiple Sclerosis Therapeutic Market: Regional Estimates & Trend Analysis
7.1. Multiple Sclerosis Therapeutic Market Share, By Region, 2024 & 2033 (USD Million)
7.2. North America
7.2.1. North America Multiple Sclerosis Therapeutic Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.2.2. U.S.
7.2.2.1. U.S. Multiple Sclerosis Therapeutic Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.2.3. Canada
7.2.3.1. Canada Multiple Sclerosis Therapeutic Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.2.4. Mexico
7.2.4.1. Mexico Multiple Sclerosis Therapeutic Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.3. Europe
7.3.1. Europe Multiple Sclerosis Therapeutic Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.3.2. UK
7.3.2.1. UK Multiple Sclerosis Therapeutic Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.3.3. Germany
7.3.3.1. Germany Multiple Sclerosis Therapeutic Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.3.4. France
7.3.4.1. France Multiple Sclerosis Therapeutic Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.3.5. Italy
7.3.5.1. Italy Multiple Sclerosis Therapeutic Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.3.6. Spain
7.3.6.1. Spain Multiple Sclerosis Therapeutic Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.3.7. Denmark
7.3.7.1. Denmark Multiple Sclerosis Therapeutic Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.3.8. Sweden
7.3.8.1. Sweden Multiple Sclerosis Therapeutic Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.3.9. Norway
7.3.9.1. Norway Multiple Sclerosis Therapeutic Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.4. Asia Pacific
7.4.1. Asia Pacific Multiple Sclerosis Therapeutic Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.4.2. China
7.4.2.1. China Multiple Sclerosis Therapeutic Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.4.3. Japan
7.4.3.1. Japan Multiple Sclerosis Therapeutic Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.4.4. India
7.4.4.1. India Multiple Sclerosis Therapeutic Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.4.5. South Korea
7.4.5.1. South Korea Multiple Sclerosis Therapeutic Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.4.6. Australia
7.4.6.1. Australia Multiple Sclerosis Therapeutic Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.4.7. Thailand
7.4.7.1. Thailand Multiple Sclerosis Therapeutic Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.5. Latin America
7.5.1. Latin America Multiple Sclerosis Therapeutic Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.5.2. Brazil
7.5.2.1. Brazil Multiple Sclerosis Therapeutic Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.5.3. Argentina
7.5.3.1. Argentina Multiple Sclerosis Therapeutic Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.6. Middle East and Africa
7.6.1. Middle East and Africa Multiple Sclerosis Therapeutic Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.6.2. South Africa
7.6.2.1. South Africa Multiple Sclerosis Therapeutic Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.6.3. Saudi Arabia
7.6.3.1. Saudi Arabia Multiple Sclerosis Therapeutic Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.6.4. UAE
7.6.4.1. UAE Multiple Sclerosis Therapeutic Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.6.5. Kuwait
7.6.5.1. Kuwait Multiple Sclerosis Therapeutic Market Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 8. Competitive Landscape
8.1. Recent Developments & Impact Analysis by Key Market Participants
8.2. Company Categorization
8.3. Company Heat Map Analysis
8.4. Company Profiles
8.4.1. Teva Pharmaceutical Industries Ltd.
8.4.1.1. Participant’s Overview
8.4.1.2. Financial Performance
8.4.1.3. Product Benchmarking
8.4.1.4. Recent Developments/ Strategic Initiatives
8.4.2. Pfizer Inc.
8.4.2.1. Participant’s Overview
8.4.2.2. Financial Performance
8.4.2.3. Product Benchmarking
8.4.2.4. Recent Developments/ Strategic Initiatives
8.4.3. Biogen
8.4.3.1. Participant’s Overview
8.4.3.2. Financial Performance
8.4.3.3. Product Benchmarking
8.4.3.4. Recent Developments/ Strategic Initiatives
8.4.4. Bayer AG
8.4.4.1. Participant’s Overview
8.4.4.2. Financial Performance
8.4.4.3. Product Benchmarking
8.4.4.4. Recent Developments/ Strategic Initiatives
8.4.5. Sanofi
8.4.5.1. Participant’s Overview
8.4.5.2. Financial Performance
8.4.5.3. Product Benchmarking
8.4.5.4. Recent Developments/ Strategic Initiatives
8.4.6. F. Hoffman-La Roche Ltd
8.4.6.1. Participant’s Overview
8.4.6.2. Financial Performance
8.4.6.3. Product Benchmarking
8.4.6.4. Recent Developments/ Strategic Initiatives
8.4.7. Johnson & Johnson Services, Inc.
8.4.7.1. Participant’s Overview
8.4.7.2. Financial Performance
8.4.7.3. Product Benchmarking
8.4.7.4. Recent Developments/ Strategic Initiatives
8.4.8. Merck & Co., Inc.
8.4.8.1. Participant’s Overview
8.4.8.2. Financial Performance
8.4.8.3. Product Benchmarking
8.4.8.4. Recent Developments/ Strategic Initiatives
8.4.9. Takeda Pharmaceuticals Company Limited.
8.4.9.1. Participant’s Overview
8.4.9.2. Financial Performance
8.4.9.3. Product Benchmarking
8.4.9.4. Recent Developments/ Strategic Initiatives
8.4.10. Horizon Therapeutics plc
8.4.10.1. Participant’s Overview
8.4.10.2. Financial Performance
8.4.10.3. Product Benchmarking
8.4.10.4. Recent Developments/ Strategic Initiatives
Cross-segment Market Size and Analysis for Mentioned Segments
Additional Company Profiles
(Upto 5 With No Cost)
Additional Countries (Apart
From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers